At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DNA Ginkgo Bioworks Holdings Inc.
Market Closed 01-09 16:00:00 EST
9.24
+0.18
+1.99%
盘后9.31
+0.07+0.80%
19:27 EST
High9.44Low9.12Vol725.34K
Open9.18D1 Closing9.06Amplitude3.53%
Mkt Cap559.85MTradable Cap383.80MTotal Shares60.59M
T/O6.74MT/O Rate1.75%Tradable Shares41.54M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?
Simply Wall St.  ·  01-10 15:16
What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?
U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, Evercore
Reuters  ·  01-08
U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, Evercore
We Think Bumitama Agri (SGX:P8Z) Might Have The DNA Of A Multi-Bagger
Simply Wall St.  ·  01-08
We Think Bumitama Agri (SGX:P8Z) Might Have The DNA Of A Multi-Bagger
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
GlobeNewswire  ·  01-06
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
National Forest and Grass Germplasm Resource Xiong'an Facility Set for Year-End Completion, First Specimens Hold Major Significance
Deep News  ·  01-04
National Forest and Grass Germplasm Resource Xiong'an Facility Set for Year-End Completion, First Specimens Hold Major Significance
Ginkgo Bioworks Names Jennifer Wipf to Oversee Operations as Reshma Shetty Shifts Focus
Reuters  ·  2025-12-24
Ginkgo Bioworks Names Jennifer Wipf to Oversee Operations as Reshma Shetty Shifts Focus
Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology
MT Newswires Live  ·  2025-12-23
Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology
A Billion-Dollar Fund's "DNA Reconstruction" Experiment: Central Huijin's Entry, Management Reshuffle, and Sustained Performance Growth
Deep News  ·  2025-12-22
A Billion-Dollar Fund's "DNA Reconstruction" Experiment: Central Huijin's Entry, Management Reshuffle, and Sustained Performance Growth
Article 6.4: a six-month deadline extension keeps PACM’s doors open to roughly 1bn CDM credits
Fastmarkets  ·  2025-12-19
Article 6.4: a six-month deadline extension keeps PACM’s doors open to roughly 1bn CDM credits
Ginkgo Bioworks and Agricen Collaborate to Optimize Soil Amendment Fermentation
Reuters  ·  2025-12-17
Ginkgo Bioworks and Agricen Collaborate to Optimize Soil Amendment Fermentation
Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment
THOMSON REUTERS  ·  2025-12-17
Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment
Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform
MT Newswires Live  ·  2025-12-09
Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform
BRIEF-Ginkgo Bioworks Holdings Inc - Selected By Pnnl To Deliver A Modular, High‑Throughput Phenotyping Platform For Doe's M2pc
Reuters  ·  2025-12-05
BRIEF-Ginkgo Bioworks Holdings Inc - Selected By Pnnl To Deliver A Modular, High‑Throughput Phenotyping Platform For Doe's M2pc
Ginkgo Bioworks Holdings Inc - Awarded by Environmental Molecular Sciences Laboratory a Four-Year, up to $47M Contract
THOMSON REUTERS  ·  2025-12-05
Ginkgo Bioworks Holdings Inc - Awarded by Environmental Molecular Sciences Laboratory a Four-Year, up to $47M Contract
Ginkgo Bioworks Holdings Inc - Selected by Pnnl to Deliver a Modular, High‑Throughput Phenotyping Platform for Doe's M2PC
THOMSON REUTERS  ·  2025-12-05
Ginkgo Bioworks Holdings Inc - Selected by Pnnl to Deliver a Modular, High‑Throughput Phenotyping Platform for Doe's M2PC
Ginkgo Bioworks Wins Up to $47 Million Contract to Build Automated Phenotyping Platform for PNNL
Reuters  ·  2025-12-05
Ginkgo Bioworks Wins Up to $47 Million Contract to Build Automated Phenotyping Platform for PNNL
Is Twist’s New Endotoxin‑Controlled Plasmid DNA Offering Altering The Investment Case For TWST?
Simply Wall St.  ·  2025-12-05
Is Twist’s New Endotoxin‑Controlled Plasmid DNA Offering Altering The Investment Case For TWST?
Twist Bioscience Introduces New Plasmid DNA Preparation Products
MT Newswires Live  ·  2025-12-04
Twist Bioscience Introduces New Plasmid DNA Preparation Products
Ginkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies
Reuters  ·  2025-12-03
Ginkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade
InvestorPlace  ·  2025-12-02
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade

Introduction

Company Name.
Ginkgo Bioworks Holdings Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--